Caplin Point Laboratories share news, announcements and annual reports
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Caplin Point Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1995 on BSE, Jun 2014 on NSE
Last close ₹2,362.80up ₹10.40 (0.44%)BSE ₹2,362.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,352.40.
28 Oct: open ₹2,352.00, high ₹2,377.10, low ₹2,330.00
52-week range of traded prices to 28 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,960 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.01
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 39,48950.3% delivered
Caplin Point Laboratories share news and announcements
492 announcements, routine notices left out, newest first. Page 4 of 10.
Sep 2023
Aug 2023
14 Aug · Management
7 Aug · Corporate action
7 Aug · Results
3 Aug · Analysts
Jul 2023
Jun 2023
May 2023
27 May · Corporate action
27 May · Board meeting
27 May · Results
22 May · Analysts
22 May · Board meeting
Meeting on 27 May 2023: “CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 27-May-2023 to consider and approve the Yearly Audited Financial results of the Company for the period end”18 May · Analysts
Apr 2023
11 Apr · Disclosure
Mar 2023
29 Mar · Business
22 Mar · Legal
The exchange asked on 20 Mar 2023
Feb 2023
11 Feb · Results
11 Feb · Board meeting
Jan 2023
28 Jan · Board meeting
Dec 2022
15 Dec · General updates
Nov 2022
27 Nov · Related Party Transaction
11 Nov · Analysts
Oct 2022
7 Oct · Legal
Exchange has sought clarification from Caplin Point Laboratories Limited with respect to announcement dated 30-Sep-2022 informing about Appointment.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the company is awaited.
Sep 2022
30 Sep · Meeting
29 Sep · Meeting
5 Sep · Corporate action
Aug 2022